Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares hit a new 52-week high on Wednesday . The company traded as high as $8.99 and last traded at $8.99, with a volume of 2,368,290 shares changing hands. The stock had previously closed at $8.97.

A number of analysts have recently issued reports on RPTP shares. Cowen and Company downgraded shares of Raptor Pharmaceutical Corp. from an “outperform” rating to a “market perform” rating and set a $9.00 price objective on the stock. in a report on Friday, September 16th. Wedbush reiterated a “neutral” rating and issued a $4.00 price objective (down from $9.00) on shares of Raptor Pharmaceutical Corp. in a report on Monday, September 12th. FBR & Co reiterated a “hold” rating on shares of Raptor Pharmaceutical Corp. in a report on Thursday, September 8th. Citigroup Inc. downgraded shares of Raptor Pharmaceutical Corp. from a “buy” rating to a “neutral” rating and lifted their price objective for the company from $6.00 to $8.00 in a report on Monday, August 8th. Finally, Zacks Investment Research upgraded shares of Raptor Pharmaceutical Corp. from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a report on Thursday, August 11th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Raptor Pharmaceutical Corp. presently has a consensus rating of “Hold” and a consensus target price of $7.93.

The stock’s market cap is $766.90 million. The firm has a 50-day moving average price of $7.50 and a 200 day moving average price of $5.73.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/raptor-pharmaceutical-corp-rptp-reaches-new-52-week-high-at-8-99.html

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.02. The firm had revenue of $32.05 million for the quarter, compared to analysts’ expectations of $28.52 million. Raptor Pharmaceutical Corp. had a negative return on equity of 66.67% and a negative net margin of 79.29%. The company’s revenue for the quarter was up 37.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS. Analysts anticipate that Raptor Pharmaceutical Corp. will post ($0.90) EPS for the current year.

Several institutional investors have recently bought and sold shares of RPTP. Geode Capital Management LLC boosted its position in Raptor Pharmaceutical Corp. by 7.0% in the first quarter. Geode Capital Management LLC now owns 573,082 shares of the company’s stock worth $2,636,000 after buying an additional 37,740 shares during the last quarter. Renaissance Technologies LLC boosted its position in Raptor Pharmaceutical Corp. by 7.5% in the first quarter. Renaissance Technologies LLC now owns 572,946 shares of the company’s stock worth $2,636,000 after buying an additional 40,066 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Raptor Pharmaceutical Corp. during the first quarter worth about $771,000. Quantitative Systematic Strategies LLC acquired a new position in Raptor Pharmaceutical Corp. during the second quarter worth about $495,000. Finally, Bank of New York Mellon Corp boosted its position in Raptor Pharmaceutical Corp. by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 455,391 shares of the company’s stock worth $2,446,000 after buying an additional 11,837 shares during the last quarter. Hedge funds and other institutional investors own 54.91% of the company’s stock.

About Raptor Pharmaceutical Corp.

Raptor Pharmaceutical Corp. (Raptor) is a biopharmaceutical company. The Company is focused on developing and commercializing transformative treatments for people affected by diseases. Its product, PROCYSBI (cysteamine bitartrate) is a delayed-release capsules for the management of nephropathic cystinosis in adults and children of over six years.

5 Day Chart for NASDAQ:RPTP

Receive News & Ratings for Raptor Pharmaceutical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raptor Pharmaceutical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.